期刊文献+

福建沿海地区人群心血管活性肽apelin水平与血压的相关性研究 被引量:3

Relationship Between Apelin Level and Blood Pressure in a Coastal Population of Fujian Province
下载PDF
导出
摘要 目的:探讨福建沿海地区人群心血管活性肽apelin水平与血压的关系。 方法:采用横断面调查方法纳入福建沿海地区30~79岁人群1031人,男性416例,平均年龄(55.1±10.9)岁,均行问卷调查、体格检查、血生化及血浆apelin水平检测。1031人根据美国最新高血压治疗指南(JNC7)的高血压定义分组:高血压组(n=496),收缩压≥140 mmHg(1 mmHg=0.133 kPa)或舒张压≥90 mmHg或已开始服降压药者;正常高值血压组(n=314):未服用降压药物收缩压120~139 mmHg和(或)舒张压80~89 mmHg;正常血压组(n=221):未服用降压药物收缩压〈120 mmHg且舒张压〈80 mmHg。1031人根据apelin四分位水平分为四组,Q1组(n=258):〈164.8ng/ml,Q2组(n=258):164.8±220.0 ng/ml,Q3组(n=258):220.0~283.1 ng/ml,Q4组(n=257):〉283.1 ng/ml。采用单因素方差分析趋势检验、协方差分析和多元线性回归分析评价血浆apelin与血压的相关性。 结果:1031人中男性血浆apelin水平[(220.57±78.87)pg/ml]比女性[(232.06±81.17)pg/ml]降低,正常高值血压组与正常血压组比较、高血压组与正常血压组和正常高值血压组比较,apelin水平均降低(P〈0.05)。Q2、Q3组与Q1组比较,收缩压、舒张压与平均动脉压均降低, Q4组与其他三组比较,收缩压、舒张压(不包括Q2组和Q3组)与平均动脉压均降低,差异均有统计学意义(P均<0.05)。调整了性别和年龄,收缩压、舒张压及平均动脉压在apelin四分位组间的差异仍有统计学意义(P〈0.05)。多元线性回归分析提示收缩压、舒张压及平均动脉压与apelin水平存在负相关,在调整了其它心血管危险因素后,这种相关关系仍然存在。 结论:apelin水平随着血压水平的升高而降低,提示心血管活性肽apelin水平与血压调控相关。 Objectives: To explore the relationship between vascular active peptide, apelin level and blood pressure in a coastal population of Fujian province. Methods: A total of 1031 subjects with the mean age of (55.1±10.9) years in a coastal area of Fujian province were included in this cross-sectional study, and 416 subjects with male gender. The questionnaire survey, physical examination and plasma level of apelin measurement were conducted. Based on JNC-7 deifnition of hypertension, the subjects were divided into 3 groups: ① Hypertension group, the patients with systolic blood pressure (SBP)≥140 mmHg and/or diastolic blood pressure (DBP)≥90 mmHg, n=496. ② Pre-hypertension group, SBP at (120-139) mmHg and/or DBP at (80-89) mmHg without medication, n=314.③Normal BP group, SBP〈120mmHg and DBP〈80mmHg without medication, n=221. Based on 4 quartiles of apelin levels, the subjects were further divided into 4 groups:Q1 group, apelin<164.8 ng/ml, n=258. Q2 group, apelin at (164.8-<220.0) ng/ml, n=258. Q3 group, apelin at (220.0-283.1) ng/ml, n=258. Q4 group, apelin>283.1 ng/ml, n=257. One way analysis of variance, covariance analysis and multivariate linear regression analysis were used to study the relationship between apelin level and BP. Results: The apelin level in male gender (220.57±78.87) pg/ml was lower than female gender (232.06±81.17) pg/ml. Compared with Normal group, Pre-hypertension group had decreased apelin level, compared with Normal and Pre-hypertension groups, Hypertension group had decreased apelin level, P〈0.05. Compared with Q1 group, Q2, Q3 groups presented decreased SBP, DBP and mean arterial blood pressure (MABP), and compared with other 3 groups, Q4 group had decreased SBP, DBP (not including Q2, Q3 groups) and MABP, P〈0.05. With adjusted age and gender, SBP, DBP and MABP were signiifcantly different among 4 quartiles of apelin groups, P〈0.05. Multivariate linear regression analysis indicated that SBP, DBP and MABP were negatively related to apelin level, such relationship remained the same after adjusting the other cardiovascular risk factors. Conclusion: Apelin level dropping accompanying with BP increasing implies that vascular active peptide, apelin involved in BP regulation.
出处 《中国循环杂志》 CSCD 北大核心 2015年第1期42-46,共5页 Chinese Circulation Journal
基金 福建省科技计划重点项目(2010y0013) 福建省医学创新课题(2012-CX-1) 福建省自然科学基金(2010J01120)
关键词 血压 心血管危险因素 流行病学调查 Apelin Blood pressure Cardiovascular risk factor Epidemiology
  • 相关文献

参考文献20

  • 1Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. Neurochero, 2000, 74: 34-41.
  • 2Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependenl mechanism. Regulatory Peptides, 2001, 99: 87-92.
  • 3Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur Pharmacol, 2003, 470: 171-175.
  • 4Lee DK, Saldivia VR, Nguyen T, et al. Modification of the terminal residue of apelin-13 antagonizes its hypotensive acti on. Endocrinology, 2005, 146:231- 236.
  • 5Barnes GD, Alam S, Carter G, et al. Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail, 2013, 6 : 482-491.
  • 6American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care, 2011, 34(Suppl): S11-61.
  • 7Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003,289:2560-2572.
  • 8Charles CJ. Putative role for apelin in pressure/volume homeostasis and cardiovascular disease. Cardiovsc Hematol Agents Med Chem, 2007, 5: 1-10.
  • 9Kleinz M J, Davenport AP. hnmunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial ceils. Regul Pept, 2004, 118: 119-125.
  • 10lshida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem, 2004, 279:26274 -26279.

二级参考文献28

  • 1李立明,饶克勤,孔灵芝,姚崇华,向红丁,翟凤英,马冠生,杨晓光,中国居民营养与健康状况调查技术执行组.中国居民2002年营养与健康状况调查[J].中华流行病学杂志,2005,26(7):478-484. 被引量:1780
  • 2Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation ,2002,105 : 1135-1143.
  • 3Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J,2000,21:1584-1590.
  • 4Schnabel R, Rupprecht HJ, Lackner KJ, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J,2005,26:241-249.
  • 5Tommasi S, Carluccio E, Bentivoglio M, et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol, 1999,83 : 1595-1599.
  • 6Mega JL, Morrow DA, De Lemos JA, et al. B-type natfiuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction : an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol, 2004,44:335-339.
  • 7Akkus MN, Polar G, Yurtdas M, et al. Admission levels of C-reac- tive protein and plasminogen activator inhibitor-1 in patients with acute myocardial infarction with and without cardiogenic shock or heart failure on admission. Int Heart J,2009,50:33-45.
  • 8Berton G, Cordiano R, Palmieri R, et al. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J, 2003,145 : 1094-1101.
  • 9Scifica BM, Morrow DA, Cannon CP, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clinical Chemistry,2007,53 : 1800-1807.
  • 10Katayama T, Iwasaki Y, Yamamoto T, et al. "Smoker' s paradox" in patients with acute myocardial infarction receiving primary coronary intervention . Cardio1,2006,48 : 193-200.

共引文献73

同被引文献9

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部